相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants
Anna M. Becker et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2023)
Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial
Robin von Rotz et al.
ECLINICALMEDICINE (2023)
Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
Friederike Holze et al.
BIOLOGICAL PSYCHIATRY (2023)
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects
Anna M. Becker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects
Malin Vedoy Uthaug et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2022)
Safety pharmacology of acute LSD administration in healthy subjects
Friederike Holze et al.
PSYCHOPHARMACOLOGY (2022)
Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
Friederike Holze et al.
NEUROPSYCHOPHARMACOLOGY (2022)
Development and validation of an LC-MS/MS method for the quantification of mescaline and major metabolites in human plasma
Jan Thomann et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2022)
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
Friederike Holze et al.
NEUROPSYCHOPHARMACOLOGY (2021)
Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders
Lea J. Mertens et al.
PHARMACOPSYCHIATRY (2021)
Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin ' s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma
Karolina E. Kolaczynska et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2021)
Trial of Psilocybin versus Escitalopram for Depression
Robin Carhart-Harris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial
Alan K. Davis et al.
JAMA PSYCHIATRY (2021)
Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin
Friederike Holze et al.
FRONTIERS IN PHARMACOLOGY (2021)
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Cato M. H. de Vos et al.
FRONTIERS IN PSYCHIATRY (2021)
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Emmanuelle A. D. Schindler et al.
NEUROTHERAPEUTICS (2021)
Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Friederike Holze et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Trends in LSD use among US adults: 2015-2018
R. Andrew Yockey et al.
DRUG AND ALCOHOL DEPENDENCE (2020)
Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
Friederike Holze et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions
Ricardo Jorge Dinis-Oliveira et al.
CURRENT MOLECULAR PHARMACOLOGY (2019)
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences
Theresa M. Carbonaro et al.
PSYCHOPHARMACOLOGY (2018)
Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics
Dino Luethi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2018)
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
Albert Garcia-Romeu et al.
INTERNATIONAL REVIEW OF PSYCHIATRY (2018)
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Matthias E. Liechti et al.
PSYCHOPHARMACOLOGY (2017)
The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation
Katrin H. Preller et al.
CURRENT BIOLOGY (2017)
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Anna Rickli et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Yasmin Schmid et al.
BIOLOGICAL PSYCHIATRY (2015)
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Frederick S. Barrett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects
Peter Gasser et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Prosocial effects of oxytocin and clinical evidence for its therapeutic potential
Nadine Striepens et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2011)
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Roland R. Griffiths et al.
PSYCHOPHARMACOLOGY (2011)
Effects of a β-blocker on the cardiovascular response to MDMA (Ecstasy)
C. M. Hysek et al.
EMERGENCY MEDICINE JOURNAL (2010)
Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV)
Erich Studerus et al.
PLOS ONE (2010)
Shamanism and San Pedro through Time: Some Notes on the Archaeology, History, and Continued Use of an Entheogen in Northern Peru
Bonnie Glass-Coffin
ANTHROPOLOGY OF CONSCIOUSNESS (2010)
Novel, unifying mechanism for mescaline in the central nervous system Electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships
Peter Kovacic et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2009)
Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose
Tomas Palenicek et al.
PSYCHOPHARMACOLOGY (2008)
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
R. R. Griffiths et al.
PSYCHOPHARMACOLOGY (2006)